v3.26.1
Segments (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of fnancial data for the company's reportable segment

The following table presents certain financial data for the Company’s reportable segment:

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

INB-100 research and development expenses

 

$

245

 

 

$

228

 

 

$

623

 

 

$

454

 

INB-200 research and development expenses

 

 

21

 

 

 

5

 

 

 

57

 

 

 

15

 

INB-400 research and development expenses

 

 

27

 

 

 

181

 

 

 

68

 

 

 

626

 

Personnel-related indirect research and development expenses

 

 

1,266

 

 

 

1,241

 

 

 

2,577

 

 

 

2,501

 

Total general and administrative expenses

 

 

2,442

 

 

 

2,714

 

 

 

5,095

 

 

 

5,402

 

Other segment items1

 

 

780

 

 

 

725

 

 

 

1,451

 

 

 

1,646

 

Segment net loss

 

$

4,781

 

 

$

5,094

 

 

$

9,871

 

 

$

10,644

 

 

Other segment items include preclinical expenses, interest income and other income.